A Pullback or a Buying Opportunity? Analyzing Vertex Pharmaceuticals’ Growth Drivers for the Coming Year Mar 25, 2026 Life Science
Who Will Be the Next Oncology Giant? Axsome and Madrigal Could Overtake by 2026 Mar 25, 2026 Life Science
Tarsus Pharmaceuticals Chief Human Resources Officer Sells Shares, Transaction Highlights Company’s Commercial Momentum Mar 25, 2026 Life Science
Eli Lilly’s Weight-Loss Bet Comes With Risk. This ETF Offers a Smarter Alternative Mar 25, 2026 Life Science
April 10 Looms as Eli Lilly’s Next Big Test: Is the Stock a Buy Before the FDA Verdict? Mar 22, 2026 Life Science
Hims & Hers Joins Hands with Former Rival, Hidden Concerns Loom Over the Weight Loss Drug Market Landscape Mar 18, 2026 Life Science
How is Pfizer Tackling the “Blockbuster Drug Drought” in the Post-Pandemic Era? Mar 17, 2026 Life Science
Insider Cashes Out, Hedge Fund Piles In: The Two Faces of Olema After a 300% Rally Mar 16, 2026 Life Science
Novo Nordisk Partners with Hims & Hers: Can Turning a Foe into a Friend Reverse the Downturn? Mar 13, 2026 Life Science
Why Microsoft Is a Safe Bet in the AI Era, Despite Moderate Stock Gains Mar 13, 2026 Life Science, Technology
Seeking a Bottom in Choppy Markets? Two Long-Term Picks with “Anti-Fragile” Qualities Mar 12, 2026 Life Science, Technology
The Obesity Drug War Goes Oral: Why Eli Lilly’s Orforglipron Could Steal the Spotlight from Novo Mar 11, 2026 Life Science
